Biodexa's 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross, Bearish Marubozu

Corbus's 15-minute chart has recently displayed a significant technical indicator, the KDJ Golden Cross, which has occurred in conjunction with a Bullish Marubozu at 10/08/2025 14:45. This suggests that the momentum of the stock price is shifting towards the upside, indicating a potential for further upward movement. The dominance of buyers in the market indicates a bullish trend that is likely to persist.

Corbus Pharmaceuticals Holdings, Inc. (CRBP), a precision oncology company, has recently shown signs of a potential upward trend in its stock price. The 15-minute chart of CRBP has displayed a significant technical indicator, the KDJ Golden Cross, which occurred on October 8, 2025, at 14:45. This indicator is often associated with a shift in the momentum of the stock price, suggesting a potential for further upward movement Top Premarket Decliners^[1].

Additionally, the chart shows a Bullish Marubozu at the same time, which indicates a strong buying pressure in the market. The dominance of buyers over sellers suggests a bullish trend that is likely to persist. This combination of technical indicators provides a strong signal for investors to consider the potential for further upward movement in the stock price of Corbus Pharmaceuticals .

Corbus Pharmaceuticals has a diversified portfolio of experimental drugs targeting solid tumors and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) targeting the expression of Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody blocking the activation of TGF-β expressed on cancer cells. The company's latest drug, CRB-913, is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity .

The company's recent performance has been mixed, with earnings results for the second quarter and six months ended June 30, 2025, reporting a basic EPS of USD -1.44. However, the FDA has granted fast track designation to Corbus Pharmaceuticals' Nectin-4 targeting ADC, CRB-701, for head and neck squamous cell carcinoma treatment, which may drive future growth .

Given the recent technical indicators and the company's promising pipeline, investors may want to keep an eye on Corbus Pharmaceuticals Holdings, Inc. for potential upside opportunities.